ETFs with exposure to CytomX Therapeutics, Inc. : November 20, 2017 Mon, 20 Nov 2017 17:07:23 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CytomX Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CTMX-US. Comparing the performance and risk of CytomX Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Mon, 13 Nov 2017 13:43:05 +0000 Categories: Yahoo FinanceGet free summary analysis CytomX Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 24.14 million, Net Earnings of USD -10.25 million. Change in operating cash flow of 59.54% compared to same period last year is about the same as change in earnings, likely no significant ... Read more
(Read more...)
CytomX Therapeutics reports 3Q loss Wed, 08 Nov 2017 00:03:36 +0000 The South San Francisco, California-based company said it had a loss of 28 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
CytomX to Present at the Jefferies 2017 London Healthcare Conference Wed, 01 Nov 2017 20:05:00 +0000 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017-- CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies ...
CytomX Therapeutics to Announce Third Quarter 2017 Financial Results Thu, 26 Oct 2017 20:26:17 +0000 SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017-- CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial ...
Cancer Space Last Week Update: Pipeline Expansion in Focus Mon, 09 Oct 2017 14:13:02 +0000 Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Analysts’ Recommendations for Amgen in October 2017 Mon, 09 Oct 2017 11:44:10 +0000 Of the 24 analysts tracking Amgen (AMGN) in October 2017, ~42% of the analysts recommended a “buy” rating, and the rest suggested a ”hold.” On October 5, Amgen had a consensus 12-month target price of ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.